The FDA on September 13, 2018 approved LUMOXITI®, a CD22-directed cytotoxin indicated for adult patients with Relapsed or Refractory Hairy Cell Leukemia (HCL) who received at least two prior systemic therapies, including treatment with a Purine Nucleoside Analog (PNA). LUMOXITI® is a product of AstraZeneca Pharmaceuticals LP.
Bottom Ad
Advertisement
Subscribe
